JULY 2021 – FINEXSI ISSUED ITS REPORT AS INDEPENDENT EXPERT IN CONNECTION WITH THE PROPOSED PUBLIC BUY-OUT OFFER FOLLOWED BY A SQUEEZE-OUT (OPR-RO) INITIATED BY CALLIDITAS THERAPEUTICS AB FOR THE SHARES OF GENKYOTEX S.A.
Following off-market block purchases, a simplified tender offer and the subscription to a capital increase, CALLIDITAS THERAPEUTICS AB held 90.3% of the shares of GENKYOTEX SA, a biopharmaceutical company specialised in the development of NOX therapies. CALLIDITAS THERAPEUTICS AB therefore announced on July 28, 2021 its intention to launch a public... Read more...